Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Merck Setting Up Asian R & D HQ

By R&D Editors | December 6, 2011

TRENTON, N.J. (AP) – Drugmaker Merck & Co. is setting up a new research and development headquarters for Asia in Beijing.

The company said that the center’s first phase, set to be completed by 2014, will have capacity for about 600 employees spread over about 506,000 square feet of laboratory and office space. They’ll be working on discovering potential new drugs, testing them in the lab and then people, getting regulatory approval and doing other research programs.

Merck says the new center is part of its $1.5 billion commitment to invest in such work in China over the next five years. The center will be in Wangjing Park, a rapidly expanding science and technology park in the Chinese capital.

“By strategically locating in China, we are able to complement our existing R&D capabilities, and facilitate new collaborations with scientists in the region and across emerging markets,” Peter S. Kim, president of Merck Research Laboratories, said in a statement.

Like most other major drugmakers, Merck sees its revenue leveling off in Western countries, so it’s aiming to boost sales in emerging markets, where governments and a growing middle class are spending more on health care. Those include the two most populous nations, China and India, as well as Russia, Brazil and Mexico.

Along with adding new sales offices in cities across China, Merck and its rivals are building new research centers there and in other parts of Asia, as well as factories that can produce medicines cheaply enough that local residents can afford them and the companies can still make a profit.

They are generally employing many local workers or setting up partnerships with local companies to help build familiarity with their brands, create goodwill with government officials and win government health program contracts.

Merck noted that two diseases that are part of its research and treatment focus, diabetes and heart disease, are becoming increasingly common in China.

The company has its commercial headquarters for China in Shanghai and has manufacturing plants at other locations across China.

Date: December 6, 2011
Source: Associated Press

Related Articles Read More >

2025 R&D layoffs tracker: 83,543 and counting
Health-related innovation in Morocco highlighted by resident inventor patenting activity
ARPA-H funds $29M Ginkgo-led project to reshore pharma supply chains using wheat germ tech
DNA microscope offers new 3D view of organisms from the inside out
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE